E. James Hutchens, CEO, President, Director
Jim Hutchens is a proven entrepreneur with over 30 years of experience in general and marketing management in the medical device industry. As the founder and CEO of Microsurge Inc., a venture-backed, minimally invasive surgery company, he assembled a management team, guided the company’s products through the regulatory process, hired a sales and marketing team, drove revenues to an annual run rate of over $10 million and sold the company. As the founder and CEO of Choice Therapeutics, an advanced wound care company, Mr. Hutchens implemented similar tactics and with revenue of $2 million sold the company to Alliqua Biomedical a NASDAQ list company. At Microvasive Endoscopy, a division of Boston Scientific, revenues rose from $300,000 to over $20 million during his tenure as Vice President, Marketing and Sales. Mr. Hutchens has also served as a senior executive at Smith & Nephew, Millipore, and CR Bard. He is a former member of the Board of Directors of the Brigham and Womens/Faulkner Hospital. He holds a BS in Business Administration from Boston University.
William Galine, Director
For the past 31 years, Mr. Galine has been involved in corporate finance and marketing. He has worked in public relations and corporate communications since 1984 as a business owner and as a consultant to public companies. Mr. Galine has been involved in helping raise over $40M in financings for multiple publicly traded companies. His combined experience and knowledge in the area of investor relations and business is an asset to Imagin Medical. He is a graduate of San Diego State University.
Dr. Robin Atlas, Director
Dr. Robin A. Atlas is Medical Director Emerita of Harvard Vanguard Medical Associates, the largest multi-specialty group practice in New England. Dr. Atlas maintained a primary care internal medicine practice at the flagship Kenmore Center from 1981 until her retirement from active clinical practice in 2001. She served as Chief of Internal Medicine for the Kenmore Office (60,000 patients, 45 clinicians, $550M budget) from 1984 until 1986, when she became the Director of Medical Specialties for the 14 offices and 350,000 patients of the then Harvard Community Health Plan. In 1994, Dr. Atlas was appointed Deputy Medical Director and, in this capacity, created the department of Utilization Management and Clinical Program Development for the Health Centers Division, which was instrumental in Harvard Vanguard’s attaining recognition as the highest performing group practice in Massachusetts on Health Care Consortium quality measures. Dr. Atlas became the Medical Director and Chief Medical Officer for the newly independent Harvard Vanguard Medical Associates in 1997, overseeing all clinical programs and personnel (900 clinicians, 4200 employees, $90M budget). Dr. Atlas was recognized with the Chief Medical Officer Emerita designation upon her retirement in 2001. Prior to joining the practice at Harvard Community Health Plan/Harvard Vanguard, Dr. Atlas received her B.S. from the University of Illinois in 1974 and her M.D. degree, awarded with Highest Distinction, from Northwestern University Medical School in 1978. She interned and completed an internal medicine residency at Boston’s Beth Israel Hospital in 1981.
Steven Chan, Director
Steven Chan is past Vice President of Cambridge House Conferences: a division of Cambridge House International Inc. He was instrumental in building Cambridge House into Canada’s leading investment conference company, serving the mining and natural resource industry. At Cambridge House he worked with all aspects of the mining industry including public companies, brokerage firms, fund managers, letter writers, analysts and retail investors. Currently he consults with public companies in the areas of financing and public relations.
Ken Daignault, Director
Ken Daignault has almost 30 years’ experience in the medical device field, with an emphasis in urology. He has held senior level management positions in major medical device companies, most recently with Boston Scientific as Director of R& D, Urology. He has also held positions at Kendall Healthcare (now Covidien) and CR Bard, one of the world’s largest urology companies. Ken has been involved in all aspects of the medical device business, from product development and the design of protocols and procedures for bench and animal pre-clinical testing, to building long-term strategies for multiple-product portfolios at various stages of development. Ken has strong relationships within the urology field and with key medical institutions, as well as a track record of bringing products from concept through successful product launch.